Innovative therapeutics

Investors

BioMarin to Participate in Three Investor Conferences in September
- Citi's 13th Annual Biotech Conference on September 5-6 in Boston
- Morgan Stanley 16th Annual Global Healthcare Conference on September 12-14 in New York City
- Jefferies Gene Therapy Summit on September 27 in New York City
Aug 22, 2018

SAN RAFAEL, Calif., Aug. 22, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in three investor conferences this September.  To access the events that are accessible by live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:


Investors                               

Media

Traci McCarty                                          

Debra Charlesworth

BioMarin Pharmaceutical Inc.                       

BioMarin Pharmaceutical Inc.

(415) 455-7558                                                      

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information